CorMedix (CRMD) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does CorMedix (CRMD) do?
CorMedix Inc (CRMD) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Commercializes an antimicrobial catheter lock solution designed to reduce bloodstream infections in kidney dialysis patients. Prevents bloodstream infections by selling a specialized catheter locking liquid directly to kidney dialysis providers. It is worth $404.05M on the market and sold $412.30M over the last year.
- Market cap
- $404.05M
- P/E ratio
- 7.7×
- Annual sales
- $412.30M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 14, 2026
Brands and businesses behind CRMD
- DefenCath: Catheter lock solution that earns revenue through sales to dialysis providers and hospital networks.
- Neutrolin: Antimicrobial catheter lock formulation marketed internationally to prevent line infections and blood clots.
CRMD’s flags, in plain English
Each flag is a number from CorMedix’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.
Wide Gross Margin
Gross margin of 77.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 319.8% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Cheap on Cash Flow
Priced at 1.3 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Heavily Shorted
19.5% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about CRMD
How big is CorMedix?
CorMedix’s market cap is $404.05M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $412.30M: what customers paid the company over the last year, before any costs.
What is CRMD’s P/E ratio?
CRMD’s P/E ratio is 7.7×. Investors pay about 7.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with CRMD?
Revenue depends almost entirely on the commercial adoption and insurance reimbursement of a single drug. That is one risk on CorMedix’s card. Its first risk flag is Heavily Shorted, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From CorMedix’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. CRMD’s filings on SEC.gov. The Margin Monkey is research, not advice.
